Company Overview
BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions.
The company's product portfolio comprises three approved products and multiple clinical and nonclinical product candidates. Approved products include Naglazyme® (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme® (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan ® (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Investigational product candidates include 6R-BH4 for cardiovascular indications, PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of PKU, and GALNS for the treatment of MPS IVA (Morquio A Syndrome).
Company Information
| Established: | 1997 |
| Headquarters: | Novato, California USA |
| Stock Symbol: | NASDAQ: BMRN |
| Stock Quote: |  More  |
2007 Financial Highlights
| Total Revenue: | $121.6 Million |
| Net Loss: | $15.8 Million |
| Net Income: | $2.6 Million |
| Employees: | 600 worldwide |
| Clinical Research: | Conducted internationally |
| Manufacturing Operations: | Novato, California USA |
| Products: | KUVAN® for PKU, Naglazyme® for MPS VI, Aldurazyme® for MPS I |
| Commercial Operations: | Multinational |
| Clinical Pipeline: | PEG-PAL for PKU, 6R-BH4 for cardiovascular indications |
| Nonclinical Pipeline: | IgA Protease for IgA Nephropathy, GALNS for MPS IVA (Morquio Syndrome), Utrophin Inducer for Duchenne Muscular Dystrophy, BH4 Prodrug for BH4 Applications, GAA for Pompe Disease |
| Focus: | Rare (Orphan) genetic diseases |
| Proven Expertise: | Strong Business Model, Product Development, Manufacturing, Clinical/Regulatory, Global Commercialization |
| Strategy: | Providing rapid access to treatment for patients with serious unmet medical needs, Optimizing powerful biology with demonstrated potential and development clarity, Accelerating approval process, Strategic pipeline development |
Products
BioMarin has developed and commercialized three products in ten years, a remarkable accomplishment in the biopharmaceutical industry, and a testament to the company’s passion and dedication to patients with serious unmet medical needs. For complete safety and prescribing information, including a boxed warning for Aldurazyme, please visit www.kuvan.com, www.naglazyme.com and www.aldurazyme.com.